Which hedge funds own NTLA? INTELLIA THERAPEUTICS INC, Q2 2026 13F holders
43 tracked hedge funds disclosed a position in NTLA (INTELLIA THERAPEUTICS INC) in their Q2 2026 13F filings, worth $572.7m in total. The largest holder by portfolio weight is Birchview Capital, LP at 3.2% of its book. 13 opened a new position this quarter: Deuterium Capital Management, LLC, RA Capital Management, L.P., Ghisallo Capital Management LLC, Baker Bros. Advisors LP. 6 exited: Seven Fleet Capital Management LP, Aquatic Capital Management LLC, Alphadyne Asset Management LP.
- 43
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 13
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 6
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $147m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $6.9m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $573m
- Combined value Sum of the holders' reported positions in the security.
- 3.5%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Seven Fleet Capital Management LP | 0.1% | $404k |
| Aquatic Capital Management LLC | 0.04% | $1.2m |
| Alphadyne Asset Management LP | 0.02% | $131k |
| ADAR1 Capital Management, LLC | 0.02% | $250k |
| Squarepoint Ops LLC | 0.01% | $2.7m |
| Balyasny Asset Management L.P. | 0.0% | $2.2m |
Ownership over time
Who discovered NTLA first? Beta
| Integral Health Asset Management, LLC | Q1 2021 | +2.6 pts |
| Pura Vida Investments, LLC | Q2 2021 | +0.3 pts |
| Sabby Management, LLC | Q1 2017 | +0.3 pts |
| Ratan Capital Management LP | Q3 2021 | −0.3 pts |
| EcoR1 Capital, LLC | Q2 2016 | −0.6 pts |
| Avidity Partners Management LP | Q2 2021 | −0.8 pts |
| MPM Bioimpact LLC high conviction | Q3 2021 | −5.3 pts |
| Darwin Global Management, Ltd. high conviction | Q2 2021 | −10.5 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.